ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1885

A Weighted Genetic Risk Score Using All Known Susceptibility Variants To Predict Rheumatoid Arthritis Risk

Annie Yarwood1, Buhm Han2, Soumya Raychaudhuri2, John Bowes1, Mark Lunt3, Dimitrios A. Pappas4, Joel M. Kremer5, Jeffrey D. Greenberg6, Robert M. Plenge7, Jane Worthington8, Anne Barton9 and Stephen Eyre10, 1Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, 5Center for Rheumatology, Albany Medical College, Albany, NY, 6Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, 7Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 8Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, 9NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 10Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis (RA) and risk

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recent advances in the identification of loci associated with susceptibility to complex disease have led to methods being developed that incorporate this information into genetic screening models to identify individuals at high risk of disease.  Here we present the first risk prediction model including all 46 known genetic loci associated with rheumatoid arthritis (RA) in Caucasian populations.

Methods:

Weighted genetic risk scores (wGRS) were created using odds ratios from 45 RA susceptibility SNPs and a HLA-DRB1 tag SNP or imputed HLA amino acids (HLA-DRB1 amino acids 11, 71, 74 and amino acids 9 at HLA-DPB1 and HLA-B). The wGRS were tested in 11,370 RA cases and 15,536 healthy controls of known genotype from the UK, USA, Sweden, Netherlands and Spain, all cases were Caucasian, over the age of 18 and satisfied 1987 ACR criteria for RA modified for genetic studies. The risk of developing RA was assessed using logistic regression by dividing the wGRS into quintiles. The ability of the wGRS to discriminate between cases and controls was assessed by receiver operator curve (ROC) analysis and discrimination improvement tests. As several of the RA susceptibility loci included in the wGRS were identified in the cohort used in this study, the wGRS were tested in an independent European cohort of 2206 RA cases and 1863 healthy controls for validation.  Validation samples were from the Consortium of Rheumatology Researchers of North America (CORRONA) registry and the Informatics for Integrating Biology and the Bedside (I2B2) centre.

Results:

Individuals in the highest risk group showed significantly increased odds of developing anti-CCP positive RA compared to the lowest risk group  (AUC 0.77, OR 18.00 95% CI 13.67-23.71).  4347 individuals were classed as high risk when all susceptibility factors were included in the model, interestingly this included 10.13% of our control population.  The wGRS was validated in an independent cohort which showed similar results (AUC 0.78, OR 18.00 95% CI 13.67-23.71).  The AUC was improved by replacing the HLA-DRB1 tag SNP with imputed HLA variation at HLA-DRB1, HLA-DPB1 and HLA-B (wGRStag AUC 0.70, wGRSfull AUC 0.77) (in CCP positive individuals). Integrated discrimination improvement tests showed an increase in sensitivity and specificity of 9% and net reclassification tests showed that including all variation in the HLA over a HLA tag SNP improves the probability of correctly identifying a high risk individual to 69.20% from 64.21% and showed an overall reclassification improvement of 58.54% between models.  Comparing the full model (in CCP positive individuals) to a model containing only imputed variation at the HLA and gender showed that the addition of the susceptibility SNPs to the model only slightly improved the ROC AUC (0.74 to 0.77 respectively). 

Conclusion:

We have shown that in RA, even when using all known genetic susceptibility variants, prediction performance remains modest; whilst this is insufficiently accurate for general population screening, it may prove of more use in targeted studies. Our study has also highlighted the importance of including HLA variation in risk prediction models.


Disclosure:

A. Yarwood,
None;

B. Han,
None;

S. Raychaudhuri,
None;

J. Bowes,
None;

M. Lunt,
None;

D. A. Pappas,
None;

J. M. Kremer,
None;

J. D. Greenberg,
None;

R. M. Plenge,
None;

J. Worthington,
None;

A. Barton,
None;

S. Eyre,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-weighted-genetic-risk-score-using-all-known-susceptibility-variants-to-predict-rheumatoid-arthritis-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology